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ABSTRACT 
Maternal use of smoking tobacco during pregnancy is one of the most important preventable 
risk factors during pregnancy. Maternal smoking is associated with alterations in autonomic 
cardiac control and long-term cardiovascular effects on blood pressure and arterial wall 
properties. Earlier studies have had difficulties in determining the specific contributions of 
prenatal and postnatal exposures, respectively, as well as distinguishing acute from chronic 
effects, as these children are frequently exposed to smoking both before birth and during 
childhood. The specific role of nicotine is also unclear as smoking contains many toxic 
combustion agents in addition to nicotine. While cigarette smoking is decreasing globally, 
other forms of tobacco- and nicotine-containing products are gaining in popularity and in 
Sweden and Norway, use of smokeless tobacco (Swedish Snus) is increasing among women.  
Snus delivers high doses of nicotine to the fetus so we hypothesized that prenatal snus 
exposure had long term cardiovascular associations with increased blood pressure, arterial 
wall stiffness, intima media thickness and altered autonomic cardiac control in the offspring. 
We also aimed to investigate the levels of nicotine and metabolites in the breastmilk of snus- 
using mothers.     
We included women from a larger national cohort with women recruited during early 
pregnancy during 2006‒2011, residing in Stockholm, Östersund and Umeå. The pregnant 
women were grouped, based on their tobacco use at inclusion, into snus users, smokers or 
tobacco-free controls. Dual users were excluded. At infant age one to two months, we tested 
the infant’s heart rate variability and also the infant’s urine and mother’s breastmilk for 
nicotine and metabolites. At child age 5-6 years, we tested heart rate variability, blood 
pressure, carotid intima media thickness and calculated arterial stiffness based on pulsatile 
changes in pressure and diameters.     
Heart rate variability showed a higher low frequency/high frequency (LF/HF) ratio, 
indicating a lower vagal activity, in infants with snus exposure in utero compared with 
tobacco-free controls and the ratio was similar to that seen in smoke-exposed children. 
Breastmilk from snus users showed high levels of nicotine and cotinine. In addition, nicotine 
was still detected in breastmilk after more than 12 hours of abstention. The snus-exposed 5‒
6- year-old children showed higher systolic blood pressure, higher LF/HF ratio and stiffer 
arterial walls than tobacco-free controls. There was no significant difference in carotid intima 
media thickness between snus-exposed children and controls.    
In conclusion, several long-lasting associations with prenatal snus exposure were discovered, 
indicating a prenatal programming of the cardiovascular function. Pregnant women should be 
recommended to abstain from all tobacco- and nicotine-containing products during the entire 
pregnancy.  
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1 INTRODUCTION 
Pregnancy is an overwhelming and emotional time. Exciting and yet a time full of anxiety 
and worries. There are recommendations for all kinds of things: restrictions of food, 
medications and drugs. At best, the recommendations are explicit, scientific and easy to 
follow, but unfortunately this is not always the case. How do you, as a snus-using mother, 
know what to do? How do you as a professional health worker, know how to advise a mother 
with a tobacco habit? 
When we started to plan this study snus was gaining in popularity and was promoted as a 
means for smoke cessation and harm reduction. Snus is a moist tobacco product for oral use, 
without any of the combustion toxins found in cigarette smoke, although it contains high 
doses of nicotine. Today, snus and other nicotine containing products are considered to be 
less harmful alternatives to smoking and a way out of a smoking habit. When discussing 
harm reduction by snus, the complex situation of being pregnant and the need to care for the 
baby’s health have been neglected. For a pregnant woman, snus is probably a better 
alternative than smoking, but is that also true for her baby?  
Cigarette smoking is a modifiable and independent risk factor for cardiovascular disease and, 
during pregnancy, one of the most important preventable risk factors for adverse birth 
outcomes. Although cigarette smoking during pregnancy is decreasing globally and is now at 
around 1.7%, there are substantial regional differences (1). In the United States and European 
countries, the prevalence of smoking during pregnancy ranges from 5‒38%, with Sweden at 
the lower end of spectrum (1). The Swedish tobacco tradition includes snus; although mostly 
used by men, snus is gaining in popularity among women of a childbearing age. The 
prevalence of snus use in pregnancy is around 1.3%, with as many as 4.7% of women 
reporting snus use 3 months before pregnancy (2).   Among the thousands of different toxins 
found in cigarette smoke, nicotine is regarded as the main culprit of the adverse effects seen 
in pregnancy. Thus, the safety of using nicotine products and even nicotine replacement 
therapy (NRT) in pregnancy is highly debatable and randomized controlled studies have not 
provided any clear answers, due mainly to lack of compliance and problems with study 
design (3, 4).  
By studying snus use during pregnancy, we could differentiate between the prenatal effects 
caused by nicotine and those caused by the combustion products in cigarette smoke. 
Furthermore, and more importantly, we avoided the confounding factor of exposure to second 
hand smoke during childhood. The interpretation of the results from studies of long-term 
effects of maternal smoking have been complicated by exposure to second hand smoke, 
leading to difficulties in separating prenatal effects from postnatal, as well as acute effects 
from chronic ones.  
The rationale for the four studies in this thesis was to explore prenatal and perinatal exposure 
to snus as regards short- and long-term association with cardiovascular function in the 
offspring.  
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2 BACKGROUND 
2.1 HISTORY OF TOBACCO 
The tobacco plant Nicotiana tabacum, native to Peru and Ecuador, has been cultivated since 
5000 B.C. The practice of smoking tobacco appears to have arisen from snuffing, i.e., 
inhaling through the nose, and the most ancient tobacco-related artifacts found are snuffing 
devices. The first Europeans smoking tobacco were the crew on Christopher Columbus’ ship 
in 1492 after reaching Cuba. However, tobacco was not just smoked or snuffed, it was 
chewed, drunk, eaten, smeared over the body and put in the eyes. It was used to keep fleas 
and bugs away, for medical reasons and for religious and social purposes. It was cultivated 
and spread all over America and Europe. Royalty snuffed tobacco for the perceived medical 
effects; ironically, it was even believed to cure and prevent cancer (5).  
Manufactured cigarettes were first marketed in England in 1850 and during the First World 
War the habit spread dramatically; use doubled in the United States during the first half of the 
20th Century. The first epidemiological reports about the association of lung cancer and 
smoking were published in 1950 (6), but it was not until 1964, when the Surgeon General’s 
report on “Smoking and Health” described the hazardous effects of smoking, that these 
became common knowledge. However, the report had little impact on smoking rates (7).  
 
Picture 1. Dried tobacco leaves. Source: Swedish Match.  
 
The estimated prevalence of smoking has decreased in the last 30 years and there has been a 
shift in the main locations of use, from high-income countries to developing countries, where 
the smoking prevalence remains high. The difference in prevalence between men and women 
is narrowing, with an increase in smoking among young women (8). Around 80% of the 1.1 
billion smokers in the world live in low- or middle-income countries (9). Out of the 7 million 
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tobacco-related deaths per year, 890,000 are deaths because of exposure to second hand 
smoke and 28% of these are children (9).    
2.2 PREVALENCE OF TOBACCO USE DURING PREGNANCY 
2.2.1 Smoking during pregnancy 
In a systematic review and meta-analysis of 295 reports published in 1985‒2016, the 
estimated global prevalence of smoking during pregnancy was low, around 1.7% (1). 
However, there were large regional differences, with the highest figures of estimated 
prevalence in Ireland (38%), Uruguay and Bulgaria (29%) (1), see Figure 1.  
The proportion of women who were daily smokers and continued smoking during pregnancy 
was 53% globally, ranging from 30% in European regions (including Russia) to 79% in the 
Western Pacific region (including China and Australia) (1). These numbers highlight that 
although the prevalence is decreasing overall, there are still countries where smoking during 
pregnancy is prevalent.  
 
 
 
Figure 1. National prevalence of smoking during pregnancy. Lange et al. Regional, 
national, and global prevalence of smoking during pregnancy in the general population: A 
systematic review and meta-analysis. Lancet 2018. Open publish under a creative common 
license. https://creativecommons.org/licenses/by-nc-nd/4.0/ and 
https://doi.org/10.1016/S2214-109X(18)30223-7.  
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2.2.2 Smokeless tobacco including snus during pregnancy 
Smokeless tobacco is prevalent and gaining popularity; it is often less expensive than 
cigarettes and considered safer. In many low- and middle-income countries, it is part of a 
long cultural tradition and used by both women and men. An estimated 300 million people 
use smokeless tobacco in different forms, most frequently in India and Bangladesh, but also 
for example among the Inuits in Canada and Alaska. The tobacco can be chewed, sucked, 
dissolved in the mouth, applied to the gums as a paste or ground into the gums. In 
Scandinavia and the United States, the most common type is an oral moist snuff (snus) which 
is put under the lip. There is also dry powder snuff that can be inhaled nasally. To avoid 
misunderstanding the word snus is used in this thesis when referring to the Swedish type of 
oral moist snuff described in detail below.     
The worldwide prevalence of smokeless tobacco use among pregnant women is not known, 
regional studies show a wide range: 33% in Orissa, India, 17% in Mumbai, India, 14% in 
Alaska, and 7% in Soweto, South Africa (10, 11). Smokeless tobacco is rare in high income 
countries, except Scandinavia where the use of snus is increasing, especially among women 
in Sweden and Norway. Although the highest prevalence of 18‒20% is seen among Swedish 
men, the Swedish National Board of Health reported in 2017 that the use among women had 
almost doubled in ten years and 4.7% of women reported snus use 3 months before 
pregnancy. The estimated prevalence of snus during pregnancy is 1.3% in Sweden, 3.4% in 
Norway and < 1% in the United States (12, 13).   
2.2.3 E-cigarettes  
E-cigarettes and water pipes (hookahs) are gaining in popularity especially among young 
people. Other forms of nicotine products are evolving on the market, like tobacco-free 
sachets, nasal sprays, lozenges, gums and patches and the line between replacement products 
and new addictive products is far from obvious. Cigarette smokers may find these products 
helpful as harm reduction but there is a substantial influx of new users to these nicotine 
products and the tobacco industry is enthusiastic in finding new products and new customers 
(14). In e-cigarettes, a fluid containing flavors and the preferred amount of nicotine is 
electronically heated and the vapor is inhaled. High school students in Sweden have reported 
occasional use of e-cigarettes (vaping) in 45% of males and 37% of females (15) and reports 
from the United States show an increased risk among adolescents to move from e-cigarettes 
to traditional tobacco cigarettes (16). A study from the United States published in 2017 
showed that at least as many pregnant women used e-cigarettes as tobacco cigarettes and the 
women viewed e-cigarettes as safer than tobacco cigarettes (17).  
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2.3 SNUS ‒ ORAL MOIST SNUFF 
2.3.1 Constituents of Swedish snus  
Snus is a moist tobacco product for oral use, packaged in small pouches or in a loose powder 
to put under the lip. All the women in the studies included in the thesis used snus pouches. 
Swedish snus contains pulverized tobacco, water, sodium carbonate, sodium chloride, 
moisturizer and flavoring(18). Compared with American snuff and other smokeless tobacco, 
Swedish snus contains significantly lower levels of toxic substances such as tobacco-specific 
nitrosamines (TSNA), polycyclic aldehydes (PAH) and heavy metals (18). The major snus 
company in Sweden (Swedish Match) has its own quality controller, Gothiatek, which 
reviews the manufacturing, packaging and storage. Gothiatek is responsible for checking that 
levels of nitrate, TSNA, PAH, aflatoxins and heavy metals are below the recommendations of 
the Swedish National Food Agency.  
 
Picture 2. Swedish snus in pouches. Photo: Niclas Grunewald 
Swedish snus delivers low doses of harmful chemicals and delivers high doses of nicotine. 
The amount of nicotine in snus varies from 3 to -12 grams per pouch, but the perceived 
strength depends on other factors, such as the acidity and humidity of the snus. Cigarette 
smoke contains around 4,000 different agents, many of which are toxic, including nicotine, 
carbon monoxide and TSNA. By burning the tobacco, carcinogenic agents like PAH and 
formaldehydes are created. The tobacco in cigarettes is acidic and must be inhaled into the 
lungs to be absorbed, while the less acidic tobacco in pipes and cigars can be absorbed more 
easily by the oral mucosa.  
2.3.2 The history of snus 
Swedes have been growing tobacco since the 17th Century and it was initially mostly used by 
the in high society. During the 18th Century, tobacco was cultivated in more than 70 Swedish 
towns. When dry snuff was replaced by moist snus, it gained popularity also among ordinary 
people and workers and the high society started to smoke cigars instead. During 1915‒1961, 
the snus industry was subject to a monopoly in Sweden and the income was initially used for 
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military needs. After World War Ⅰ, snus consumption reached an all-time high with a yearly 
consumption of 1.2 kg per person, after which snus use declined in favor of cigarettes. In 
1970, snus began to be sold in portions (small pouches) as a less messy alternative to loose 
snus and slowly gained in popularity again. Since 1992, the European Union (EU) has banned 
snus and when Sweden joined the EU in 1995, a national exception was made. In 2002, the 
snus ban was legally challenged, unsuccessfully, in the European Court of Justice. 
 
 
Figure 2. Volumes of cigarettes and snus sold in Sweden 1916‒2016. Published with 
permission from Swedish Match.  
 
2.3.3 Snus prevalence  
The use of cigarettes has decreased in Sweden in the last 30 years, while snus use has 
increased. Consequently, the total tobacco use in Sweden is at the same high level as in many 
other European countries, around 20% (19).  
Snus use among women has increased in Sweden and, in 2016, 4.7% of women reported 
using snus 12 weeks before pregnancy, an increase from 2.4% in 2007, according to the 
Medical Birth Registry (MBR) (2). There are large regional differences in Sweden, with the 
counties of Norrbotten and Västerbotten reporting 17% of women using snus 12 weeks 
before pregnancy. The age group reporting the highest snus use was women 25-29 years of 
age. The reported number of women using snus during pregnancy is around 1.3%, again with 
large regional differences. For example, in the small town of Lycksele (8,000 citizens) as 
many as 23% of the women used snus during pregnancy (2).   
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The information in MBR is based on self-reports, with prospectively collected data 
minimizing the risk of recall bias. However, given the increasing knowledge of detrimental 
effects of tobacco use during pregnancy there is a risk of underreporting. Gunnerbeck et al. 
showed in the original cohort study, named the SNUS study, that self-reporting was valid, but 
that many of the snus users were misclassified as non-users in the MBR, especially in late 
pregnancy (20). MBR has collected data about snus use during pregnancy since 2000, but 
there is no information about snus dose and the question about tobacco use could be 
misinterpreted to refer to cigarette use. In addition, there are regional differences in the 
reporting of tobacco, with a high percentage of non-response in some counties. A study from 
the United States concluded that health care staff neglected to screen for smokeless tobacco 
and other nicotine containing-products and that the knowledge of adverse pregnancy 
outcomes was limited (21).    
 
   
Figure 3. Prevalence snus use and smoking in Scandinavia in 2017-2018. More women 
than men smoke in Sweden. Sources: Public Health Agency of Sweden 
(Folkhälsomyndigheten), Statistics Norway (Statistisk sentralbyrå ,SSB), Danish Health 
Authority (Sundhetsstyrelsen) adapted by Swedish Match.    
 
2.3.4 “The Swedish experience” 
The tobacco-related mortality is lower in Sweden than in other European countries, although 
the total tobacco consumption is similar. This phenomena has been called the “Swedish 
Experience”. This is claimed to reflect that “Swedes don´t smoke as much as others because 
they use snus” and is used to promote snus as an effective method of  harm reduction (19),  
see Figure 4. The discussion is ongoing among politicians, public health experts and 
researchers, and there is no easy answer as to whether snus is an effective way out of a 
smoking addiction. Snus is an addictive tobacco product with suggested associations to some 
forms of cancer, although the overall risk of cancer is lower than for smoking cigarettes (22, 
0
5
10
15
20
25
Snus users Smokers
Sweden Norway Denmark
Daily use men, percent
0
5
10
15
20
25
Snus users Smokers
Sweden Norway Denmark
Daily use women, percent
 8 
23). There is no evidence that snus is associated with increased risk of hypertension, 
myocardial infarction or stroke (24). However, the outcome after myocardial infarction is 
worse when snus use is continued afterwards, due to increased risk of arrhythmias (25). There 
are studies describing an association between snus use and metabolic changes such as insulin 
resistance and increased risk of diabetes type 2 (26), although the latter finding is challenged 
by other reports (27, 28).  
Other forms of smokeless tobacco (SLT) have been associated with an increased risk of 
cancer in the airways and upper digestive canal and also an increased risk of stroke (29). A 
large review of worldwide studies of deaths caused by SLT report that South East Asia is a 
region with a substantial risk of death caused by SLT, due to cancer, ischemic heart disease 
and stroke (30). The regional differences in risk may be explained by various types of SLT 
used, with variations in content and route of absorption (30).    
 
Figure 4. The proportions of cardiovascular mortality attributable to tobacco in European 
males in death rates /100 000 men. Source: Swedish Match. Adapted from World Health 
Organization (WHO): Mortality Attributable to tobacco, 2012 (19).  
 
There is little direct evidence of Swedish snus or plain nicotine use in healthy adults 
contributing to poorer health (31, 32). However, the evidence from animal research and in 
vitro settings is very strong of nicotinic volatile actions and supports the notion of nicotine as 
an addictive toxin leading to an increased risk of cardiovascular disease as well as cancer (33, 
34).  
The risks associated with snus use during pregnancy are discussed below.  
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2.4 PRENATAL SNUS EXPOSURE AND PERINATAL OUTCOME 
Maternal smoking during pregnancy is associated with increased risk of spontaneous 
abortion, ectopic pregnancies, placenta previa, placental abruption and placental dysfunction 
(35). The placental problems are partially responsible for the increased risk of stillbirth and 
preterm birth seen in smokers. The increased risk of preterm birth in combination with 
growth restriction is partially responsible for the increased risk of stillbirth and neonatal death 
(36). Maternal snus use is also associated with preterm birth (37-39). On the other hand, snus 
is not associated with placenta previa or abruption and, importantly, the impact on fetal 
growth is not as strong as in maternal smoking (11, 40), see Table 1. 
There is also an interesting difference in association with preeclampsia, with smoking having 
a protective effect and reduced risk of preeclampsia, which snus use does not (38, 41). Taken 
together, this implies that there are combustion products explaining the differences between 
smoking and snus use. Carbon monoxide is suggested to be involved in the protective 
mechanism for preeclampsia and is probably also involved in the placenta problems and fetal 
growth restriction (41, 42).      
The association between cigarette smoking and the risk of malformations is not very strong, 
but some studies have demonstrated associations with oral cleft, clubfoot, anal atresia, 
gastroschisis, heart defects (atrial septal defects, pulmonary stenosis), pyloric stenosis, 
craniosynostosis, limb reduction defects, hernia and undescended testes (43, 44). There is 
only one study of the association with snus and malformations, indicating increased risk of 
oral cleft (45). No studies are available of possible associations between other forms of 
smokeless tobacco and congenital malformations in humans. 
Many of the risks mentioned above are dose-dependent and if smoking or snus use ceases 
during early pregnancy, several of the risks are reduced or eliminated (43, 46). 
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Increased risk 
of: 
Smoking: Snus: References smoking: 
(43, 44, 47-52) 
References snus: 
(37-40, 45, 46, 53) 
Stillbirth 
 
 
  (Marufu, Ahankari, 
Coleman, & Lewis, 
2015; Pineles, Hsu, Park, 
& Samet, 2016) 
(Baba, Wikstrom, Stephansson, & 
Cnattingius, 2014; Wikstrom, 
Cnattingius, & Stephansson, 2010) 
Preterm birth   (Ion & Bernal, 2015; Ko 
et al., 2014; Wallace, 
Aland, Blatt, Moore, & 
DeFranco, 2017) 
(Dahlin, Gunnerbeck, Wikstrom, 
Cnattingius, & Edstedt Bonamy, 
2016; England et al., 2003; 
Wikstrom, Cnattingius, Galanti, 
Kieler, & Stephansson, 2010) 
Small for 
gestational age, 
low birth 
weight 
  (Ko et al., 2014; Pereira, 
Da Mata, Figueiredo, de 
Andrade, & Pereira, 
2017) 
(Baba, Wikstrom, Stephansson, & 
Cnattingius, 2013; England et al., 
2003) 
Oral cleft   (Hackshaw, Rodeck, & 
Boniface, 2011; Leite, 
Albieri, Kjaer, & Jensen, 
2014(48, 54-56)) 
(Gunnerbeck et al., 2014) 
Neonatal death   (Dietz et al., 2010; 
Pineles et al., 2016) 
(Baba et al., 2014) 
Sudden infant 
death 
syndrome 
 
 ? (Chong, Yip, & 
Karlberg, 2004; Dietz et 
al., 2010; Haglund & 
Cnattingius, 1990) 
 
Table 1. Prenatal smoking or snus exposure and neonatal outcome. The broad arrows 
indicate a strong correlation while the thin arrows indicate a weaker correlation. 
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2.5 SUDDEN INFANT DEATH SYNDROME 
Sudden infant death syndrome (SIDS) is defined as the sudden death of an infant under one 
year of age that remains unexplained after autopsy, investigation of the scene of death and 
review of the medical history (57). SIDS is a subcategory of sudden unexpected death of 
infancy (SUDI), which encompasses any sudden or unexpected death occurring during 
infancy, whether explained or unexplained. SUDI includes causes of death such as asphyxia, 
suffocation, infection, metabolic disease or ion channel disease.  
The mounting of extrinsic and intrinsic risk factors during a critical developmental time 
period increases the risk for SIDS. Intrinsic factors suggested are male sex, prenatal smoke 
exposure, preterm birth and genetic polymorphism. Extrinsic factors are sleeping position, 
soft bedding and bed sharing. The “theory of the triple risk” for SIDS describes the complex 
relationship between an infant’s pathological vulnerability and an unsafe sleeping 
environment in combination with a critical developmental period (58). After the “back to 
sleep” (supine sleeping) campaign in 1992, maternal smoking became the most important risk 
factor, with an almost threefold increased risk in babies to smoking mothers before the 
campaign, jumping to a fivefold risk increase afterward (59). 
Since the supine sleeping campaign, the number of SIDS events has decreased. Still, it is the 
leading cause of death among infants from 1 month up to 1 year in the United States (around 
0.49/1,000 births) and in Sweden (around 0.15/1,000 births) (60, 61).  
The exact mechanism of how maternal smoking increases the risk of SIDS is not yet 
understood. It has been suggested that nicotine binds to endogenous nicotinic acetylcholine 
receptors expressed in the fetal brain from gestational weeks 4‒5. When these receptors are 
inappropriately stimulated by nicotine, the processes of cell survival, neurite outgrowth, 
synapse formation and transmitter release are affected (62-64). Many theories include some 
common mechanisms involving serotonergic pathways in the brainstem leading to 
disturbances in arousal and autonomic and cardiorespiratory control (56, 65, 66). Findings in 
brainstems of SIDS victims include delayed maturation of synapses in respiratory centers, 
delayed neural maturation and decreased serotonin (5-HT) receptors consistent with 
abnormalities in autonomic regulation (60, 67). In addition, a reduced lung capacity following 
prenatal nicotine exposure resulting in chronic hypoxia has been described (60, 68). Nearly 
two-thirds of SIDS victims showed structural evidence of pre-existing, chronic low-grade 
asphyxia and biochemical markers of asphyxia at autopsy (68, 69).    
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Figure 5. Schematic summary of potential interactions between environmental and genetic 
risk factors for SIDS. Printed with kind permission from the authors and CMAJ. Hunt et 
Hauck 2006 (66). 
 
Maternal smoking is associated with disturbed autonomic cardiac control, impaired arousal 
and neonatal apneas in the infant. Nicotine is suggested as the main toxin mediating these 
effects, this is supported by a vast number of animal studies. Nevertheless, snus has not been 
associated with SIDS, although a Swedish study of snus-exposed infants showed an 
association with apnea diagnosis (70).   
  
2.6 LONG-TERM EFFECTS OF MATERNAL TOBACCO USE  
Parental smoking and exposure to second hand smoking have a causal relationship with 
asthma in a child (71). Other respiratory problems such as bronchiolitis, pneumonia and 
coughing are also described (72, 73). Several studies suggest an association between 
exposure to smoking in utero and asthma during childhood (74, 75). However, most of these 
studies struggle with the confounding factor of second hand smoke exposure during 
childhood, as most parents who smoke during pregnancy continue to do so during the 
upbringing of the child.  
Overweight and higher BMI (body mass index) in the offspring of smoking mothers have 
been reported (76, 77). Neurobehavioral problems, such as attention deficit disorder and poor 
school performance, are also reported following parental smoking (78, 79).  
Increased thickness of the carotid intima media, an early sign of an atherosclerotic process, 
has been found in adolescents and young adults with a history of parental smoking (80). 
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Lastly, parental smoking has also been associated with acute lymphoblastic leukemia in 
childhood and brain tumors diagnosed before 2 years of age (81, 82). Maternal snus and its 
possible long-term associations have not been studied before. 
 
2.7 NICOTINE  
2.7.1 Nicotine pharmacokinetics and metabolism 
  
Figure 6. Acetylcholine (left) and nicotine (right). 
 
Nicotine occurs naturally in tobacco leaves and was used as an effective pesticide until 
banned by the EU in 2009. Nicotine makes up about 1.5‒3% of dry tobacco. An average 
cigarette contains 10‒14 mg nicotine and around 1‒2 mg is absorbed when smoking 
depending on the puffing of the smoker (83). Nicotine is a weak base with a pH of around 8 
and its absorption through biological membranes is pH-dependent. The smoke from a 
cigarette is acidic and nicotine is ionized and not easily absorbed by oral mucosa. The smoke 
from pipes and cigars is more alkaline and therefore more easily absorbed in the mouth. 
When cigarette smoke reaches the alveoli in the lungs it is absorbed and reaches the 
circulation quickly. After a puff from a cigarette nicotine reaches the brain in 10‒20 seconds, 
faster than via an intravenous injection. The nicotine concentration in the blood increases 
rapidly and reaches a peak within ten minutes. The nicotine concentration can be manipulated 
by the smoker on a puff-to-puff basis and that is why a smoker can extract more or less 
nicotine from the same nicotine-containing cigarette (84).  
A pouch of snus contains 4‒12 mg of nicotine and the absorbed nicotine dose depends on the 
pH, the amount of moisture, the time in contact with mucosa and how the pouch is moved 
around in the mouth. Estimated extraction of the nicotine content ranges between 30 and 60% 
(85). The absorption from oral moist tobacco is slower than from cigarettes; the peak occurs 
within 30 minutes, but the serum concentration remains at a high level for longer (86), see 
Figure 7. Absorption of nicotine from snus occurs mainly through the oral mucosa; nicotine 
swallowed is poorly absorbed in the stomach.  
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Figure 7. Blood nicotine concentrations during and after cigarette smoking for 9 minutes, 
oral snuff 2.5 g, chewing tobacco 7.9 g, and nicotine gum 4 mg. Reprinted from Benowitz et 
al. 1988. With kind permission from the author and American Society for Clinical 
Pharmacology and Therapeutics.  
 
Nicotine is easily absorbed through the skin, which is a well-known problem in tobacco 
harvesting. Green tobacco sickness occurs when in contact with the moist tobacco leaves, 
with symptoms of nicotine poisoning, such as nausea, vomiting and headaches. The 
transdermal absorption mechanism is used for nicotine patches and although the absorption is 
high, it takes one hour before nicotine is found in blood and there is no peak. This slow 
administration without a peak allows the central nervous system (CNS) to adapt and the risk 
of addiction is nil (87).    
Nicotine is metabolized in the liver by the cytochrome P450 system. There are findings 
suggesting a potential metabolism of nicotine and cotinine in other tissues than the liver, for 
example the brain and fetal lungs, but their contribution to the metabolism is considered 
small. The most important metabolite is cotinine, almost 80% of nicotine is metabolized to 
cotinine in humans and approximately 10% of the nicotine is excreted in the urine. Cotinine 
is also metabolized in the liver by the CYP2A6 enzyme, with trans-3-hydroxycotinine (OH-
cot) being the major cotinine metabolite found in urine. The ratio between OH-cot and 
cotinine is used as an estimate of the metabolic rate of the CYP2A6 enzyme and nicotine 
metabolism (84). The large differences found in nicotine metabolism both intra- and inter-
individually are explained by genetic factors, race, gender, age, pregnancy and additives like 
menthol flavoring. The half-life of nicotine is around 2 hours, whereas it is 16 hours for 
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cotinine. The long half-life of cotinine has made it commonly used as a biomarker for  
estimating nicotine exposure (84).  
Women have a higher metabolism of both nicotine and cotinine than men and the metabolism 
is even higher during pregnancy (88). A higher metabolic rate increases the need for more 
nicotine, leading to a greater challenge for a woman to quit nicotine during pregnancy. 
Another aspect of the pregnancy-induced metabolism is that lower levels of biomarkers 
(nicotine and metabolites) in urine or serum does not necessarily mean lower consumption in 
pregnancy (88). A higher rate of metabolism is also seen in women using oral contraceptives 
than in non-pregnant women not taking hormones (89).  
The metabolism of nicotine in neonates is slower, with a half-life 3‒4 times longer than in 
adults. Interestingly, the half-life of cotinine seems to be similar in neonates and adults. This 
discrepancy in metabolism is suggested to be a consequence of different enzymatic activity or  
tissue distribution (90).   
Nicotine easily passes through the placenta into fetal circulation, where around 20‒30% of 
the blood is shunted via the ductus venosus bypassing the liver and directed to the brain via 
fetal shunts (91). Nicotine is suggested to accumulate in amniotic fluid. Luck et al found 50% 
higher concentrations of nicotine in amniotic fluid compared with in maternal serum, but the 
extent of absorption through the skin of the fetus is unknown (92). The exact pathways of 
absorption and metabolism in the fetus are thus not well-described. Animal models may not 
be optimal for testing nicotine metabolism during pregnancy as their metabolism may differ 
from humans (93). Serum concentrations in fetal cord blood were 15% higher than maternal 
concentrations measured in the third trimester (92). In conclusion, the fetus is exposed to 
equal or higher levels of nicotine as compared with the mother.  
Nicotine in serum and breastmilk reaches a steady state within minutes. Nicotine is also 
accumulated in breastmilk with a ratio of 2.9, while cotinine is found in breastmilk with a 
ratio of 0.8 (94). The nicotine-containing breastmilk is swallowed by the infant; the 
absorption in the stomach is presumably low, but data is insufficient. The urinary cotinine 
levels found in breastfeeding infants of smoking mothers were 10 times higher than levels 
from bottle-fed infants of smoking mothers (95). According to Luck et al. the half-life of 
nicotine in breastmilk was almost 100 minutes, while the half-life in serum was 80 minutes 
and cotinine remained at the same levels in breastmilk over the course of 4 hours (94). 
2.7.2 Nicotinic effects 
The acute physiological effects of nicotine include cardiovascular responses with an increase 
in heart rate, cardiac contractility, respiratory rate, muscular blood flow and blood pressure. 
The systemic and cutaneous vessels contract and urine production diminishes. The platelets 
are activated and the immune system is suppressed. The effects on the CNS involve enhanced 
concentration and alertness and a suppression of appetite (86). These effects are described by 
snus users as a “pleasant feeling of being relaxed and more alert at the same time.”    
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Figure 8. Nicotinic acetylcholine receptor with nicotine and acetylcholine binding sites 
marked on the α-subunits. Adapted from Hurst et al. 2012, reprinted with kind permission 
from Elsevier.  
 
Nicotine binds to endogenous nicotinic acetylcholine receptors (nAChR) present in the brain, 
autonomic nervous system and neuromuscular junctions, and also in non-neural tissues such 
as endothelial cells, airway epithelial cells, inflammatory cells and keratinocytes (96). The 
receptor is composed of five subunits, which may vary but include at least two α-subunits on 
which the nicotine binding site is located. Nicotine binds to the outside of the receptor and 
opens the central canal, mediating an influx of sodium and calcium and an efflux of 
potassium (97).  
There is also a ligand-gated receptor in non-neural cells with signaling through 
phosphorylation. The effects of these different types of nAChRs vary, where the cholinergic 
system in the CNS involves cognitive function, memory, attention and emotional processing. 
In the autonomic nervous system nAChRs are found in the brainstem and preganglionic 
connections involved in regulation of respiration, heart rate and contractility, and blood 
pressure. The non-neural cholinergic system is critical in controlling cell proliferation, 
differentiation, migration and apoptosis (98).  
 
2.7.3 Effects of nicotine during fetal development 
The varying and complex actions of nicotine are even more intriguing and somewhat 
different during vulnerable developmental periods such as fetal life (98). The nAChRs are 
present in the brain of fetus as early as gestational week 4-5 (63). Acetylcholine is important 
for the maturation of the brain and nicotine acts as a potent neuro teratogen when interacting 
with the trophic function of the cholinergic systems (99). Nicotine binding to nAChRs affects 
other signaling systems as well, such as the serotonergic and dopaminergic systems (96). 
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Neural cell replication and differentiation, apoptosis and migration are all important 
developmental steps in the formation of the nervous system and they may all be altered by 
nicotine exposure with long-term consequences (99, 100). Prenatal nicotine exposure is also 
suggested to affect the cardiovascular system, lung volume and size, endocrine and 
immunological system and cause epigenetic changes (98). 
The full extent and precise mechanisms of prenatal nicotine exposure are not fully 
understood, although animal research and studies of children of smoking mothers have 
provided substantial insights. The timing and the dose may have importance and the effects 
are further complicated by adjustments with an initial upregulation with more nAChRs that 
eventually leads to a functional downregulation (101, 102). Not only nicotine may be of 
importance in prenatal exposure; the metabolite cotinine can also bind to nAChRs, with 
slightly different effects from nicotine. The significance of cotinine binding is not known 
(103).    
   
2.8 AUTONOMIC NERVOUS SYSTEM AND CARDIOVASCULAR REGULATION 
The autonomic nervous system (ANS) influences the function of almost all tissues in the 
body, by innervation of smooth muscle cells, cardiac muscle and pacemaker cells, exocrine 
and endocrine glands, lymphatic tissue, liver cells and white and brown fat. Without any 
conscious effort required, it regulates many physiological processes, including blood flow, 
blood pressure, heart rate, airway resistance, body temperature, metabolism, fluid balance, 
immune system, inflammatory processes, sexual function and pupil diameter (104, 105).   
The two anatomically and functionally different branches of the ANS, the parasympathetic 
and the sympathetic nervous systems, can function antagonistically, synergistically or 
independently. We often think of the sympathetic nervous system (SNS) as a “fight and 
flight” reaction but actually there is ongoing sympathetic activity even in resting conditions. 
Similarly, the parasympathetic nervous system (PNS) is not only active in “rest and digest” 
situations.  
 
2.8.1 ANS and cardiovascular regulation 
In the heart, the SNS and PNS have mainly counteracting effects, controlling heart rate, AV 
node conduction and contractility. The effects of the SNS are mediated via adrenergic 
receptors. The dominant β1 adrenergic receptors are expressed in the sinoatrial node (SA 
node), AV node and on atrial and ventricular cardiomyocytes. The activation of β1 receptors 
increases heart rate, atrial and ventricular contractility and AV node conduction velocity. In 
addition, activation of this receptor also induces renin release by the kidneys. β2 adrenergic 
receptors are mainly expressed in vascular smooth muscle, skeletal muscle and in the 
coronary circulation and elicit vasodilatation with increased blood flow to the liver, heart and 
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muscles. These non-innervated receptors are stimulated by circulating epinephrine. The 
adrenergic α1 and α2 receptors are expressed in vascular smooth muscle and elicit 
vasoconstriction (104, 105).  
The main neurotransmitter for the PNS is acetylcholine in both preganglionic and 
postganglionic neurons. Acetylcholine is excitatory, mediating its effects via nAChRs in 
ganglion synapses and in skeletal muscle cells. In addition to the nAChRs there are two kinds 
of muscarinic AChRs in the cardiovascular system. The M2 type is expressed in nodal and 
atrial tissue and also in the ventricles. Acetylcholinic activation of these receptors decreases 
heart rate and reduces AV node velocity and may also reduce contractility in the atria. The 
M3 receptor is mainly expressed in the vascular endothelium and when activated stimulates 
nitric oxide (NO) production, resulting in vasodilatation.   
Cardiovascular function is also influenced by numerous endocrine hormones. The adrenal 
gland releases norepinephrine, epinephrine and dopamine in response to sympathetic 
activation. The renin-angiotensin-aldosterone system (RAAS) is important for blood pressure 
control and renin is released by the kidney after sympathetic stimuli and activates the RAAS.  
Antidiuretic hormone is released by the posterior pituitary gland and stimulates water 
retention by the kidneys. There are also hormones released by the heart: atrial natriuretic 
peptide (ANP) from the atria and brain natriuretic peptide (BNP) from the ventricles, which 
both respond to increased stretch of the heart and inhibit catecholamine (104, 105). 
The most important reflex involved in autonomic cardiovascular function is the baroreceptor 
loop. Baroreceptors in the aortic arch and carotid bodies respond to stretching and the afferent 
signal is conducted to the CNS and vital centers in the medulla oblongata that interact with 
the endocrine response, respiratory control and arousal. In a simplified description (see Figure 
9), a fall in blood pressure is sensed by the baroreceptors and the signal is connected to 
efferent sympathetic fibers in the medulla, stimulating the heart to raise the heart rate and 
contractility to increase cardiac output. At the same time, the SNS stimulates the smooth 
muscle cells in vessels to contract and increase resistance, with additional help from 
catecholamines released from the adrenal medulla and stimulation of the RAAS.  
All these actions lead to an immediate response with increased blood pressure. This system 
works the other way as well, if blood pressure increases, the PNS will decrease the cardiac 
output. These systems work together in fine tuning of blood pressure homeostasis in daily 
life. In hypertension, the baroreceptors will adapt to the new situation and the baroreceptor 
loop will only react to deviations from the hypertensive situation (104, 105). For a further 
discussion of the ANS and blood pressure, see Results and Discussion.     
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Figure 9. Schematic picture of the baroreceptor loop. The baroreceptor signal from the 
aorta and carotid sinus is conducted via vagal (X) and glossopharyngeal (IX) nerves and 
coupled with centers in the medulla (NA: nucleus ambiguous. RVLM, CVLM: rostral and 
caudal ventrolateral medulla). Parasympathetic and sympathetic nerve input to the heart 
increases or decreases cardiac output and interacts with the renin-angiotensin-aldosterone 
system (RAAS) and total peripheral resistance (TPR) to modify blood pressure (BP). Picture 
modified from Kaur et al 2016 (106).   
 
2.8.2 Indices of autonomic nervous system activity and heart rate variability  
Some of the commonly used assessment methods of ANS function are based on triggering of 
the cardiovascular reflexes through altering blood pressure and baroreflex responses. These 
interventions include the Valsalva maneuver, carotid massage and tilt-test and mainly assess 
the sympathetic response. A noninvasive approach that provides information on both the PNS 
and the SNS is spectral analysis of beat-to-beat fluctuations in heart rate, which can be used 
in both healthy and sick individuals of all ages. 
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Picture 3. ECG (electrocardiogram) recording in a participant (non-tobacco-exposed 
control) from Study 1. The ECG recording was used for a HRV analysis. Published with kind 
permission from the parents. Photo: Felicia Nordenstam 
 
The heart rate is regulated by the PNS in resting conditions on a beat-to-beat basis; the 
signaling from the PNS acts directly on the next heartbeat and there are constant small 
fluctuations in the pace between every heartbeat. These small fluctuations appear at different 
wavelengths and are used in heart rate variability (HRV) analysis, where the most well-
known fluctuations are connected to breathing and called respiratory sinus arrhythmia (RSA). 
The RSA appears within the high frequency (HF) range and changes in the HF spectrum band 
are considered to reflect changes of parasympathetic activity. The activity in the low 
frequency (LF) band is suggested to reflect a combination of sympathetic and 
parasympathetic activity on blood pressure control, body temperature, circadian rhythms and 
the renin-angiotensin-aldosterone system.  
The ratio of LF/HF is often used as an estimate of the balance between the sympathetic and 
parasympathetic system. This interpretation needs to be used carefully and combined with 
information on the activity in the LF and HF bands, respectively. A high LF/HF ratio can be 
indicative of either a high sympathetic activity, a low parasympathetic activity or a 
combination of both. The very low frequency (VLF) band is even less understood, but 
activity in this band is unaffected by sympathetic blockade and is suggested to correspond to 
an intrinsic activity of the heart (107). In 1996, Malik et al. defined standards of HRV 
measurements in a Task Force of the European Society of Cardiology and the North 
American Society of Pacing and Electrophysiology; this document is still the gold standard 
for HRV (107). The details of HRV analysis and the technical aspects are not discussed here, 
for further reading, see Paper Ⅰ and the Task Force 1996 (107). 
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HRV analysis is a frequently used method in studies for testing autonomic function, stress 
and as a prognostic tool for cardiac conditions. In adult patients with early stages of chronic 
heart failure (CHF), a significant increase in LF and decrease in HF has been reported, 
corresponding to an altered autonomic balance with less vagal influence. The lack of vagal 
protection is considered to explain the increased risks of arrhythmia and sudden death and is 
used as a negative prognostic sign (108). Severe heart failure patients show reduced activity 
also in LF areas and in very advanced stages of CHF the heart behaves in a similar way to the 
cardiac denervation seen in patients with recently transplanted hearts (109). The re-
innervation of a transplanted heart after 1‒2 years is usually of sympathetic origin, but 
respiratory rhythmic changes have been observed. Altered HRV has been described in 
diabetes, hypertension and as a predictor of risk for sudden death (107). Children with uni-
ventricular hearts and Fontan surgery have been shown to have lower HF and the HRV could 
predict future risk of arrhythmias (110).  
Studies in preterm babies showed decreased HRV and preterm babies improved their HRV 
after massage with a more pronounced effect in males (111). Preterm birth is suggested to 
delay the maturation of the PNS, which continues during infancy (112-114). Altered HRV 
with lower vagal activity and elevated sympathetic activity in preterm infants of smoking 
mothers has been reported (115). 
 
2.8.3 Prenatal programming and DOHaD 
The idea of cardiovascular disease in the adult originating from fetal malnutrition sprang 
from Barker’s observation in 1986 of the similar geographical distribution between infant 
mortality in the early 1900s and cardiac ischemic deaths 60 years later (116). The Barker 
hypothesis described that malnutrition in fetal life with a low birth weight correlated with 
blood pressure and arterial compliance in adult life (117).  
Preeclampsia, placental dysfunction and maternal smoking are other risk factors associated 
with poor fetal growth and low birth weight. Exposure to a suboptimal environment in utero 
may affect the fetus during critical stages of development and thus cause a long-term effect 
on organs and function, a process known as prenatal programming. This concept has 
developed beyond malnutrition and now also includes overweight and obesity during 
pregnancy. 
During the last years, an even wider concept has been introduced, called Developmental 
Origins of Health and Disease (DOHaD). The DOHaD concept includes factors affecting the 
fetus or child during development and is not confined to intrauterine events. The underlying 
mechanisms are still obscure, but involvement of glucocorticoids, sex hormones, RAAS, 
ANS, oxidative stress and inflammation have been suggested (118). Altogether, early 
developmental influences affecting future health are increasingly considered to be explained 
by epigenetics (118, 119).   
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3 AIMS 
The general aims of this thesis were to explore long-term cardiovascular function in children 
with exposure to snus in fetal life by assessing autonomic cardiac regulation, blood pressure 
and arterial wall properties. We also aimed to investigate the concentration of nicotine and 
metabolites in the breastmilk from snus using mothers.  
The specific aims were: 
 To study heart rate variability (HRV) in infants with prenatal exposure to snus or 
cigarette smoke. The hypothesis was that both snus and smoke exposed infants had 
an altered HRV compared to tobacco-free controls. Paper Ⅰ. 
 To estimate nicotine, cotinine and OH-cotinine concentrations in breastmilk from 
snus using and smoking mothers before and after tobacco use. The hypothesis was 
that snus users had as high or higher concentrations of nicotine and metabolites in 
breastmilk compared to smokers. Paper ⅠⅠ. 
 To study blood pressure and heart rate variability in 5-6 years old children exposed to 
snus in fetal life. The hypothesis was that snus exposed children had higher blood 
pressure and altered heart rate variability compared to tobacco-free controls. Paper 
ⅠⅠⅠ. 
 To study carotid artery dimensions, carotid intima media thickness and arterial 
stiffness in 5-6 years old children with prenatal exposure to snus in fetal life. The 
hypothesis was that snus exposed children had thicker intima media, smaller arterial 
dimensions and stiffer arterial walls compared to tobacco-free controls. Paper Ⅳ. 
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4 METHODOLOGICAL CONSIDERATIONS 
The methods used in the studies are described in the articles and will not all be discussed in 
this chapter. Rather, the focus will be on the general outline of the studies, reasons for 
choosing certain methods and the limitations and strengths of the methods.    
4.1 ETHICAL CONSIDERATIONS 
Ethical approvals from the local ethical committee in Stockholm were obtained for all studies 
before they commenced. Written informed consent was collected from all parents. Children 
above 5 years of age were informed and asked directly. All studies were performed in 
accordance with the World Medical Association Declaration of Helsinki. 
All tobacco-using women were offered tobacco cessation advice during pregnancy via the 
antenatal clinic without any connection to the study. None of the researchers involved in the 
studies have any connections to the tobacco industry.  
4.2 STUDY DESIGN AND SETTING 
Three of the studies in this thesis are of prospective observational design (cohort studies) and 
one is a case-control study. The participants originated from a larger national study of 
prenatal smokeless tobacco exposure (SNUS). The women in the original SNUS cohort were 
included when first visiting an antenatal clinic early in pregnancy. Recruitment took place 
2006‒2011 in several parts of Sweden and a total of 474 women were included.  
 
Figure 10. Flow chart and time line for the four studies included in the thesis.  
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Based on their tobacco use when first visiting the antenatal clinic, they were classified as 
either snus users, cigarette smokers or tobacco-free controls. No dual users or users of any 
other nicotine source than cigarettes or snus were included. During pregnancy, the women 
answered questionnaires about tobacco habits and perinatal data were collected by the 
Swedish Medical Birth Register. 
4.2.1 Women and infants included in the HRV and breastmilk studies  
Women in the counties of Stockholm and Östersund were informed in early pregnancy about 
the possibility of being contacted after delivery with an invitation to a study of their 1‒2- 
month-old child (Studies 1 and 2). Families with a healthy newborn were contacted and 
informed about the study and new informed consent was collected from the mother. The 
appointment was scheduled at the pediatric ward when the baby was 6‒8 (± 2) weeks.  
All families contacted accepted the invitation to participate in Study 1 and those who were 
breastfeeding at the time of the appointment were invited to participate in Study 2.  
The optimal timing of testing was set to 6‒8 weeks after birth, as breastfeeding and daily 
routines and physiological adaptations after birth were expected to be settled at that time. We 
also expected any physiological influence of tobacco withdrawal after birth or any other 
impact on the autonomic nervous system from the “stress of being born” to have faded. 
Furthermore, as the risk for sudden infant death syndrome (SIDS) sharply increases at one 
month of age, we assumed that the alterations in autonomic control that are potentially 
associated with an increased risk of SIDS could be detected at that age (58, 66).  
A potential problem with the timing was that the autonomic nervous system (ANS) is not 
fully matured at birth, especially not the parasympathetic part. There are suggestions of a 
developmental autonomic shift around the age of one to two months; thus we may have 
introduced a bias of different maturing in the ANS (120). However, when performing sub-
group analysis with age as the variable, we could not see any association with age in weeks 
and HRV. 
The women were divided into three groups based on their tobacco habits at inclusion early in 
pregnancy around gestational weeks 7‒10. The pattern of use during pregnancy varied, with 
some women managing to quit during early pregnancy or decrease their daily dose. In 
contrast, some women increased their use during pregnancy. Thus, the tobacco exposure of 
the fetus could differ over time. There were no dual users or other nicotine containing 
products used. Furthermore, the amount of nicotine to which an infant is exposed depends on 
the route of exposure. For example, snus-using mothers who chose not to breastfeed their 
infants did not further expose their infants to any nicotine after birth. In contrast, smoking 
mothers who did not breastfeed still exposed their infants to nicotine via second hand smoke.  
The breastfeeding women were asked to abstain from tobacco use for 12 hours before the 
appointment in the pediatric ward early in the morning. However, this turned out to be 
challenging for many of the women, especially the snus users, and hence the period of 
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abstention varied between 30 minutes and 12.5 hours. In addition to introducing a variable 
time of abstention not part of the study design, this also underlines the highly addictive 
properties of nicotine. 
A concern with the testing of breastmilk is that samples collected for a couple of minutes 
from one breast might not have a representative concentration. The foremilk is more aqueous 
with lower fat content than the hind milk and the content of weak bases as nicotine might be 
lower than in the rest of the milk. To make sure to measure a true concentration of the 
breastmilk it would be preferable to empty the breast and then take a sample from the whole 
amount of milk. Further, an approach with repeated samples over a time period of 30 minutes 
could have provided more information about the highest levels of concentrations.       
 
 
Figure 11. Flowchart for inclusion for Study 1. Time line from inclusion at top, to 
examination at bottom. At inclusion the pregnant women were categorized based on their use 
of snus or cigarettes. After inclusion, some tobacco-using women quit during pregnancy 
(lighter blue for snus and lighter purple for smokers in the figure). After birth, the exposure of 
the infants in the snus group, depended on whether they were breastfed or not. The complex 
crossing after birth displays that one snus user started using snus again and two smokers 
started smoking after delivery. In the snus group there was one duplex pregnancy.   
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4.2.2 Preschool children included in the HRV, BP and carotid artery studies  
In Studies 3 and 4, women from the original SNUS cohort were again recruited, this time 
only women residing in the counties of Umeå or Stockholm. Women with a healthy 5‒6-
year-old child were invited to participate. We chose the county of Umeå as had many women 
included in the SNUS cohort, and there were identical ultrasound machines at the two 
centers. The inclusion criteria were strict in order to exclude as many confounding factors as 
possible. Exclusion criteria were any of the following: preterm birth, low birth weight, 
multiple birth, malformations or chronic health issues or exposure to second hand smoke 
during childhood, see Figure 12.  
 
Figure 12. Flowchart Study 3 (BP and HRV) and Study 4 (arterial wall properties). There 
were 42 children included in the studies, 40 children in the BP and arterial wall analysis and 
30 children in the HRV analysis.  
 
We chose the age of 5‒6 years so the child would be able to collaborate in achieving a high 
quality ultrasound examination of the carotid artery and because of the availability of 
reference data for that age group. All of the appointments were scheduled in the daytime and 
most in late afternoon. The time limit for each appointment was 60 minutes and included 
measuring weight, height, BP, ultrasound examination of the carotid artery and the heart, 
setting up the 24-hour ECG, giving information about the study and completion of a 
questionnaire by the parent during the ultrasound examination.  
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4.3 COHORT SIZE AND POWER 
The cohort size for Study 1 was based on an earlier study on heart rate variability in infants 
(121). To attain 80 % power with a 5% significance level and expecting a mean difference in 
LF/HF of 1.15 with a standard deviation of 0.95, we estimated that 54 participants would be 
sufficient. For Studies 3 and 4, we estimated that 40 subjects would be sufficient, assuming 
the same power and significance levels and a mean difference in systolic blood pressure of 4 
mmHg with a standard deviation of 6 and a difference in strain of 4% with a SD of 5 (122, 
123).  
However, when trying to do subgroup analysis the power was not sufficient. This proved to 
be an overall problem in all four studies. There were several interesting research questions 
based on subgroup analysis that we had not anticipated when planning the studies and where 
the data did not have enough power to enable any conclusions. For example, with more 
participants we could have explored differences between boys and girls further. In addition, 
in the breastmilk analysis we could see a tendency towards higher nicotine and cotinine 
concentrations in snus users compared with smokers, but it did not reach statistical 
significance, possibly representing a Type II error (β error). All four studies had limited 
numbers of participants and therefore limited possibilities for further stratified analysis.  
 
4.4 TOBACCO USE SELF-REPORTED THROUGH QUESTIONNAIRES 
The women answered questionnaires about their tobacco use at three separate occasions 
during gestation: at the antenatal booking in early pregnancy, in late pregnancy and 
immediately after birth. The participants in Studies 1 and 2 also answered a questionnaire 
concerning postnatal use at the study appointment 1‒2 months after birth. The women 
reported daily use of tobacco for each gestational week, including the name/brand of the 
tobacco product, any other source of nicotine and exposure to second hand smoke 
(hours/day). The snus dose was reported as number of pouches per day and categorized as 
follows: not daily, 1‒2, 3‒4, 5‒6 or ≥ 7 pouches per day. The cigarette dose was reported as 
number of cigarettes per day and categorized as follows: not daily, 1‒5, 6‒10 or > 10 
cigarettes per day. The women were informed that their urine might be tested for cotinine in 
late pregnancy and that both breastmilk and infant urine would be tested at the appointment 
1‒2 months after birth. 
When analyzing the data, the cut-offs for the dose categories for snus use were found to be 
set too low. There were women using up to 20 pouches per day and the high dose cut-off at > 
7 pouches per day might have blunted the dose-response testing. Errors like this can be 
identified and corrected by early sub-analysis during enrollment.  
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4.5 HEART RATE VARIABILITY (HRV) 
There are several non-invasive methods for testing autonomic cardiovascular regulation, e.g. 
the tilt-test, cardiovascular reflex tests (Valsalva maneuver and controlled breathing) and 
HRV. The cardiovascular reflex tests require cooperation from the subject and are therefore 
not applicable in infants. The tilt-test is used in testing infants, but is time-consuming and 
needs a special set-up that is not easily moved between different locations. HRV has become 
the most popular method used for autonomic cardiac assessment, even more so now than 
when we initially planned the studies. HRV is simple to perform in infants with the recording 
done at home after setting up the recorder at a hospital and does not require any adjustments 
in day-to-day life.  
HRV is widely used and the number of published scientific papers using the method is 
impressive. In 1996, HRV guidelines were published by the European Society of Cardiology 
and the North American Society of Pacing Electrophysiology (107), yet there are 
considerable variations in how HRV is performed. The inconsistency is even larger when 
performed in pediatric populations, which makes it highly important to describe the method 
in detail and use a careful approach when comparing results from different studies.  
In our studies we preferred a long-time HRV because short-time HRV (2-10 minutes) has too 
many confounding factors and a substantial risk of not detecting changes in the low 
frequencies. We focused on frequency domains (please see Introduction for further 
description), which are often used clinically in the pediatric population. After discussing and 
consulting with technical engineers with expertise in HRV, we decided to analyze a two-hour 
segment during night time sleep. In those two hours, we expected to have periods of both 
active sleep and quiet sleep and an elimination of major interferences such as noise, light and 
movement.  
Two hours is in the range of a long-time HRV and therefore we used Fast Fourier 
Transformation (FFT) analysis with the time epoch set to 5 minutes and window processing 
using Bartlett. When analyzing short-time HRV, auto regression is used and window 
processing is not necessary. All 24 hours of recording were carefully edited manually, all 
beats corrected and artifacts rejected with the nicotine status blinded for the trained analyst. 
The selected two-hour segment was recorded between 22 pm and 6 am, artifact-free and with 
a low heart rate indicating sleep. The heart rate changes during this two-hour period indicated 
different states of sleep, although this is not a validated method for sleep state evaluation 
(124).  
The respiratory peak is found in the high frequency band. The breathing frequency of an 
infant is high, around 40 breaths per minute and may even reach up to 60 breaths per minute. 
According to the Task Force, the upper limit for the HF band should be set at 0.5 Hz (based 
on HRV in adults), which leads to a potential risk of missing the respiratory peak in the infant 
(125). To make sure that we covered even high respiratory rates, we did additional analyses 
with the cut-off at 0.8 Hz. Surprisingly, doing so did not add any additional data or change 
the results, and we therefore reported our data using the Task Force limits of the HF band. In 
our HRV analysis, the respiratory peak shown as respiratory sinus arrhythmia (RSA) was not 
as dominant as expected in any of the infants. The explanation for this is not clear, either the 
RSA is not very dominant at 1‒2 months of age or we failed to detect it. Infants have a 
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different breathing pattern with elements of periodical breathing that may explain the lack of 
a prominent RSA as seen in older children and adults. This theory is supported by other 
studies of infants who were also deficient in RSA in the HF band (113). Interestingly, in a 
study from 1989, Schechtman et al. reported that the RSA diminishes during the first month 
after birth to slowly increase again after 1‒2 months (120). 
In planning the studies of the older children the same design was used and a two-hour 
segment of ECG during night time sleep was analyzed. The preschool children showed a 
typical respiratory peak as expected at a frequency of around 0.26 Hz.    
     
4.6 OSCILLOMETRIC BLOOD PRESSURE 
The gold standard for noninvasive blood pressure measurement is by sphygmomanometry of 
the brachial artery. Many of the reference tables with sex, age and height corrected values are 
based on sphygmanometric measurements. These may differ from the measurements of 
oscillometry devices, which are the most common in clinical practice nowadays. The guide 
lines from the American Academy of Pediatrics and update on the 2004 “Fourth report on the 
Diagnosis, Evaluation and Treatment of High Blood pressure in Children and adolescents” 
recommend using a validated oscillometric device, and to use a sphygmanometer to verify 
any suspicion of hypertension (126, 127). Oscillometric devices are easy to use and accepted 
for research use. We used Dinamap (GE Health Care, Fairfield, Connecticut, USA) for blood 
pressure measurement and the reference tables from the Fourth report for sex-, age- and 
height-corrected values presented in centiles.  
We followed a strict protocol with systolic blood pressure (SBP) and diastolic blood pressure 
(DBP) measured after 15 minutes of calm adaptation to the examining room and with the 
child sitting down resting. Three consecutive measurements in the right arm with at least one 
minute between the measurements were obtained by a trained nurse who was blinded to the 
category of the child. The BP was only tested at this single appointment and could have been 
influenced by other factors such as anxiety, including “white coat hypertension.” Although 
we do not know anything about the BP over time, we found a difference at the appointments 
between the snus-exposed and the controls. Other studies imply that an anxiety reaction or 
white coat hypertension also might matter in the long run (128). 
 
4.7 VASCULAR ASSESSMENT WITH B-MODE ULTRASOUND 
The ultrasound examination of the 5‒6 year-old children included a B-mode ultrasound of the 
right carotid artery and a full echocardiographic examination of the heart, to exclude any 
unknown cardiac abnormalities. All the examined children had normal results. All 
ultrasounds were performed by the same trained sonographer (Felicia Nordenstam) who was 
blinded to the group category.  
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In both centers a Philips iE33 ultrasound machine with a linear high-frequency vascular probe 
(15 Hz) and simultaneous ECG recording was used for the vascular assessments. Loops of 3‒
5 heart cycles were stored digitally on CDs for later calculations. The examination of the 
carotid intima media thickness (cIMT) was performed in accordance with the AEPC 
recommendations with the child in supine position, with the neck slightly extended. The 
artery was identified in short axis view and then examined in long axis view with the carotid 
bulb identified; the region of interest was the intima media in the far wall for a segment of 10 
mm, proximal to the carotid bulb. 
Three recordings of the common carotid artery were saved and used for later analysis. The 
cIMT was measured in end diastole (129) identified through ECG and the mean of three 
separate measurements was calculated with a max, mean and SD of cIMT for each participant 
using the semi-automated software Arterial Health Package from Siemens. Many reports 
emphasize the importance of using special software for these calculations. Considering that 
the layers measured in children were 380‒420 µm and that the axial resolution in a high 
frequency probe was approximately 0.3‒0.5 mm, manual measurements raise questions about 
validity of results.    
The carotid dimensions were measured from leading edge to leading edge of the adventitia in 
systole and late diastole based on the ECG recording in long axis view. The carotid artery 
strain was calculated as the relative pulsatile diameter change (delta D) using the formula:  
Peak systolic diameter (ESD) – end-diastolic diameter (EDD) / EDD X 100 
The stiffness index (beta) for the carotid artery was calculated using the formula: 
ln (SBP/DBP) / (ESD-EDD/EDD)(123, 130) 
One limitation with the carotid examination was that only the right artery was examined. This 
decision was taken as we examined 5-year-old children and wanted them to be comfortable 
and at ease during the examination. Studies of the carotid artery in children do not describe 
any differences in strain, stiffness or cIMT (131-133) between the right and left carotid artery, 
although examination of both arteries are recommended for evaluation of cIMT (134). There 
is one study in adults reporting different impact of ageing on cIMT, where the left carotid 
artery displays changes earlier than the right (135). Some studies of cIMT and association 
with cardiovascular risk factors show differences between right and left cIMT(136, 137). 
These studies do not provide any explanation for the incongruences and the findings are 
described in general terms. The theoretical background for the diversity is different 
anatomical origins for the vessels and different hemodynamic impact due to the different 
anatomies. Furthermore, fetal circulation provides a potential difference in blood flow and in 
oxygen and nutrient content of the circulation in carotid arteries is accentuated during periods 
of circulatory redistribution (“brain sparing”) when blood from the ductus arteriosus might 
contribute to the circulation of the brain via retrograde circulation in the isthmus. Whether 
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there are any important differences in cIMT, strain or stiffness between the two carotid 
arteries needs further exploration.   
   
4.8 STATISTICAL METHODS 
The statistical methods used in the studies are described in detail in each paper. Descriptive 
statistics were presented as means and standard deviations and medians and ranges or 
interquartile ranges for numerical variables, or as frequencies for categorical variables. 
Differences between groups were examined using the chi-squared test or Fischer’s exact test 
for categorical variables. Student’s T-test and the Mann-Whitney U-test were used for 
comparing two groups and one-way ANOVA for comparing three groups with continuous 
variables. Further analysis with Tukey’s post hoc pairwise comparison was made if the 
overall ANOVA test was significant. Correlations were tested with Pearson’s correlation or 
Spearman’s correlation.  
Multiple linear regression was employed to control for potential confounders. The dependent 
variable and relevant clinical and demographic explanatory variables were tested with a 
systematic approach. In a simple linear regression model the relationship between the 
predictor variables and outcome was examined and thereafter the variables whose univariate 
test had a P-value <0.1 were considered candidates for further testing along with clinical 
relevant variables. The variables identified were entered into a multivariate model.  
In the first paper the effect size was calculated with partial η2 (eta squared). When presented 
with a difference between groups, a reader wants to know whether it is large or small. The P-
value provides information on whether a finding is significant and not caused by chance; it 
does not include information on if the finding or difference is of importance. This 
consideration is even more important when using large cohorts, where a very large cohort can 
show a significant difference even if the difference is very small and may not be of clinical 
importance. An oversized cohort was not a problem in our studies, though some of our 
outcomes were more difficult to interpret than others. For example, it is easy for most readers 
to realize that a mean difference of 5.4 mmHg in SBP is quite large. On the other hand, the 
LF/HF ratio is much harder to grasp, making it difficult to understand if the mean difference 
of 1.16 is small or large. In ANOVA, analysis of partial η2 is an appropriate method for 
estimating effect size and our result was 0.22; values above 0.14 are considered large (138).
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5 RESULTS AND DISCUSSION 
The most important results and conclusions from the papers included in the thesis are 
presented and discussed in this section. For complete results for all studies, see the published 
papers and manuscripts. 
5.1 MAIN FINDINGS 
The rationale for the studies in this thesis was to explore prenatal and perinatal exposure to 
smokeless tobacco (Swedish snus) and subsequent cardiovascular function in the infant/child. 
We explored autonomic cardiac regulation in 1‒2-months-old infants and also estimated 
exposure by analyzing nicotine and metabolites in infants’ urine and mothers’ breastmilk. 
Snus-exposed infants were compared to tobacco-free controls of same age; infants of 
smoking mothers were also tested. 
Furthermore, a group of 5‒6-year-old children with snus exposure in fetal life, and no 
additional tobacco exposure after weaning from breastfeeding, had their blood pressure, 
autonomic cardiac regulation and characteristics of the carotid artery evaluated. 
Several long-lasting associations with prenatal snus exposure were discovered indicating a 
prenatal programming of cardiovascular function. These findings included an altered 
autonomic cardiac regulation, higher systolic blood pressure and stiffer arterial walls 
following prenatal snus exposure compared with in tobacco-free controls.  
 
5.2 TOBACCO ALTERS AUTONOMIC CARDIAC REGULATION WITH 
DECREASED PARASYMPATHETIC ACTIVITY 
The autonomic cardiac regulation was explored through spectral analysis of HRV and we 
found a higher LF/HF ratio in infants at one to two months of age following snus exposure 
compared with tobacco-free controls (Paper Ⅰ). The higher LF/HF ratio was mainly explained 
by a lower power in the high frequency domain, indicating decreased parasympathetic 
activity. The LF/HF ratio did not differ between snus- and smoke-exposed infants, which 
suggests that nicotine, the common constituent in tobacco, mediates the impact on autonomic 
regulation regardless of absorption route.  
Other studies of infants with smoking mothers report similar findings with a higher LF/HF 
during sleep in infants aged 6‒16 weeks (139) and abnormal heart rate response to tilt-tests in 
infants aged one to three weeks and three months (140). This has been considered a sign of 
autonomic instability. However, interpretation is complicated by the fact that reference values 
for HRV variables in children are scarce, mainly due to differences between studies in 
methodology, age and sex. A study of 201 children from 3 days to 14 years with a long time 
HRV showed coherence with our HRV data in infants (LF/HF ratio 2.15) and 5‒6 year-old 
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children (LF/HF ratio 0.7) (141). It is not possible from to draw any conclusions from these 
studies about what should be categorized as risk values.  
 
 
Figure 13. LF/HF ratio in controls (n = 19) and snus (n = 23) and smoke-exposed (n = 12) 
infants. Results from Study 1.  
 
Although not fully understood, autonomic dysregulation is considered to be a crucial 
component in the multifactorial mechanisms underlying SIDS (142). Studies of infants who 
experienced apparent life threatening events (ALTE) or later succumbed to SIDS revealed 
changes in HRV indicating an immature or altered parasympathetic tone (143-146). Factors 
influencing autonomic control may thus have the potential to increase the risk for SIDS, and 
parental smoking is the major risk factor for SIDS following the sleeping campaigns (56, 57, 
147, 148). This raises the question of whether other tobacco forms or nicotine containing 
products are safe. Snus use during pregnancy is associated with increased risk of intrauterine 
death and apneas although increased risk of SIDS has not been described (53, 70). 
Among the several thousands of toxins in cigarette smoke, nicotine is the major neurotoxic 
substance. It binds to endogenous neuronal nicotinic acetylcholine receptors in the fetal brain 
and brainstem (63, 149-151), with consequences such as impaired arousability (65, 152), 
altered parasympathetic control (149, 153) and impaired autonomic cardiac control (154, 
155). All these pathophysiological effects may have implications for the risk of SIDS.   
During fetal life and in the newborn the sympathetic drive tends to dominate. As the ANS 
matures the parasympathetic influences increase and modulate the autonomic balance with 
increasing age (156, 157). Our findings suggested a decreased parasympathetic activity and 
we postulated that there was either a delay in the ANS maturation due to nicotine exposure or 
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a long-term alteration of the ANS. At the time of publication, there were several studies 
supporting a delay in maturation, but a long-term effect from nicotine could not be ruled out. 
A study by Cohen et al. suggested long term effects on autonomic control up to one year of 
age, although the children in that study were continuously exposed to second hand smoke 
(140). Our results, showing altered autonomic activity in 5‒6 year-old children with perinatal 
snus exposure (Study 3), support the theory that it is a long-term effect that may have 
implications beyond the risk period of SIDS. There are also more recent studies suggesting 
long-term effects on autonomic activity in adults who were born preterm (158). 
 
5.2.1 Even early prenatal exposure matters ‒ there are no safe periods 
There were no differences found between the snus and smoke groups and we therefore 
merged the two tobacco groups to study the timing of exposure. Infants were divided into 
three new groups: prenatal early exposure, prenatal continuous exposure and prenatal plus 
postnatal exposure. Eight women managed to quit during the first or second trimester and 
were classified as “prenatal –early.” Seven women did not expose their infants to any tobacco 
after birth, they were either smoking women who quit or snus users who did not breastfeed. 
The group of infants exposed in fetal life but not after birth were classified as “prenatal –
continuous.” The group with both pre- and postnatal exposure included 20 children with an 
active ongoing exposure at the time of testing, classified as “prenatal plus postnatal.”  
All three groups with tobacco exposure had higher LF/HF than the control group. Even the 
prenatal -early group, which had no exposure for the last 4‒9 months, had a higher LF/HF 
ratio compared with controls. See Figure 14. 
To our knowledge, a lasting effect from nicotine exposure limited to early gestational 
exposure only has not been described in humans before and indicates a prenatal programming 
with a long-term effect on autonomic control. Most animal studies have included both 
prenatal and postnatal exposure. This is in many ways similar to the situation for infants of 
smoking mothers, where children will be exposed also postnatally via second hand smoke. 
Studies of maternal smoking and snus use has suggested that terminating exposure in 
pregnancy may reverse negative effects on birth weight, risk of stillbirth  or preterm birth and 
other risks for the infant (40, 43, 46, 159). Our findings indicate that early exposure is also of 
importance. This leads to the conclusion that there may be no time periods that are “safe” 
regarding nicotine exposure and consequently that tobacco cessation programs need to be 
implemented before conception.  
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Figure 14. Tobacco exposure (smoking and snus) in different periods in fetal life and 
after birth and the association with HRV. Results from Study 1.   
 
 
The prenatal -continuous group had an even higher LF/HF ratio than the prenatal -early 
group. This suggests either a dose-response effect, where this group have been exposed to a 
higher total nicotine dose than the prenatal -early group, or an impact of exposure during 
sensitive developmental periods in fetal life. Mid-gestation has been suggested as a 
vulnerable period with a rapid change in the profile of nicotine receptor subtypes in the 
brainstem (160). A recent study in rats tested exposure to second hand smoke and 
neurotoxicity during three periods of gestation, reporting a small effect from premating 
exposure, an intermediate effect from early gestation and a large effect from late gestation 
(161), a pattern similar to our findings.  
A more puzzling finding was that the group with previous and acute exposure (prenatal plus 
postnatal) had a significantly lower LF/HF than the prenatal continuous group, albeit still 
higher than the controls and on a level comparable to that of the prenatal -early group. One 
possible explanation may be that a signaling system accustomed to high nicotine levels resets 
and adapts to a new situation when depleted of nicotine. Another possible explanation is that 
breastfeeding has a positive impact on the LF/HF ratio, either per se or via a breastmilk 
constituent. Breastfeeding protects against SIDS and the effect is stronger if the baby is 
exclusively breastfed (162). There are studies supporting a theory of different autonomic 
function in breastfed infants compared with formula-fed, but the results are inconclusive 
(163, 164). These findings should be explored further and corroborated, as they may point to 
mechanisms of intervention that could be of importance.  
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5.3 HIGH LEVELS OF NICOTINE AND METABOLITES ARE FOUND IN 
BREASTMILK FROM SNUS- USING MOTHERS 
Breastmilk from breastfeeding women and urine from infants were analyzed for nicotine and 
its metabolites cotinine and OH-cotinine. At the time of testing (⁓ 6 weeks after birth), 19 out 
of 24 snus- exposed infants and 11 out of 13 smoke- exposed infants were breastfed, as were 
all the non- exposed infants (Paper Ⅰ). Breastfeeding is generally recommended even for 
mothers using tobacco- or nicotine- containing products, as the beneficial effects are 
considered to outweigh the potential risks. Nevertheless, breastfeeding is less common 
among smoking mothers than tobacco-free mothers with multifactorial explanations 
including concerns of nicotine passing to breastmilk, decreased milk production and a higher 
incidence of colic (165-167). Our finding that snus- using mothers breastfed to a lower extent 
may have similar reasons, but this was not explored in the present studies. 
We found high concentrations of nicotine and its metabolites in breastmilk from snus users 
with the highest nicotine levels around 30 minutes after snus use (Paper ⅠⅠ). The highest 
detected concentrations of nicotine (137 ng/mL) and cotinine (958 ng/mL) were found in 
breastmilk from snus users, but the overall median concentrations did not differ from in 
smoking mothers. Furthermore, while breastmilk samples from smoking mothers were all 
nicotine-free after four hours of abstention, samples from snus- using mothers had detectable 
levels up to 12 hours of tobacco abstention. A plausible explanation for this is the plateau of 
high nicotine concentrations seen in snus users, described earlier, and that accumulated 
nicotine in other tissues continues to contribute to the concentrations found in breastmilk. The 
balance between serum and breastmilk may shift back and forth, with levels of nicotine 
remaining high for a longer time.   
Trying to time breastfeeding before taking pouch of snus is probably better than the opposite, 
but these findings indicate that levels will remain high. Thus, cutting down doses or quitting 
will be far more effective in reducing the nicotine content in breastmilk.   
The urine of the infants contained high concentrations of cotinine and OH-cotinine in both 
tobacco groups without any differences between the groups. The metabolites found in the 
infants’ urine are likely a result of both the infants’ own metabolisms and direct exposure to 
metabolites via the breastmilk. Previously, cotinine and OH-cotinine have been considered to 
lack physiological effects. However, recent studies in rats have suggested that the 
physiological effects of cotinine seem to counteract those of nicotine, where cotinine lowers 
heart rate and BP and weakens adrenergic vasoconstriction (168, 169). If that is true also in 
humans, the lower response in LF/HF seen in infants with postnatal exposure may be 
mediated by acute cotinine exposure. Analyzing cotinine and OH-cotinine may thus be of 
importance in future studies, in order to understand the findings and draw clinical 
conclusions.    
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5.4 A HIGHER SYSTOLIC BLOOD PRESSURE IS SEEN FOLLOWING 
PRENATAL SNUS EXPOSURE 
Children aged 5‒6 years who were exposed to snus in fetal life had a higher SBP than 
tobacco-free controls (Paper ⅠⅠⅠ). The mean difference in SBP was larger than in other studies 
of parental smoking and BP and remained high after the SBP was corrected for age, sex and 
height (126, 127). See Figure 15. There were two snus- exposed children with an elevated 
SBP (>90th centile) and none in the tobacco-free group. Since blood pressure development 
during the lifespan follows a trajectory, a minor change in blood pressure as a child might 
become larger later in life (170-172). At a population level, a minor change may have 
significant importance for the prevalence of hypertension and cardiovascular disease. DBP 
did not differ between the groups, although there was a trend towards higher DBP in the 
snus- exposed children.  
 
 
Figure 15. SBP in snus exposed (n = 21) and control children (n = 19). The SBP is age-, 
sex- and height- adjusted and presented in percentiles. Results from Study 3. 
 
 
   
Although no significant difference was found in weight or BMI, there was a trend towards 
higher BMI in snus- exposed children. Overweight, high BMI and obesity have been 
described in children exposed to smoking (76, 77). Simonetti et al. reported some of the most 
important factors for higher SBP in children including overweight, preterm birth or low birth 
weight and maternal smoking (173). We found a correlation between SBP and weight for 
both snus-exposed children and tobacco-free controls. See Figure 16.    
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Figure 16. The correlation between weight and SBP. Results from Study 3.  
 
Acute exposure to nicotine raises the blood pressure, but in chronic tobacco users the blood 
pressure control seems to be more complicated. Some studies have even reported lower BP in 
adult smokers than in controls (174). Maternal smoking during pregnancy has been 
associated with higher BP in exposed children, considered to be a long-lasting effect from 
prenatal nicotine exposure. However, these studies struggle with the confounding factor of 
continued exposure to second hand smoke during childhood, which complicates 
interpretation (77, 175-178). In exploring snus exposure during pregnancy and breastfeeding 
we were able to eliminate both the influence of combustion toxins from cigarette smoke and 
that of second hand smoke exposure during childhood. Our results reveal a long-lasting 
association between perinatal nicotine exposure and a higher SBP in the offspring as a result 
of prenatal programming.  
  
5.5 STIFFER ARTERIAL WALLS ARE ALSO SEEN FOLLOWING SNUS 
EXPOSURE 
In addition to a having a SBP, the snus-exposed children displayed stiffer arterial walls and 
lower strain than the tobacco-free children (Paper Ⅳ). Arterial stiffness describes the loss of 
elasticity of an artery with an incapability to respond to pressure changes and is influenced by 
several parameters, such as hypertension, smoking, obesity and duration of breastfeeding 
(179-183). Both acute and chronic changes with increased arterial stiffness have been 
reported in adults smoking (180), using nicotine-containing electronic cigarettes or nicotine 
tablets (184-186).  
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Figure 17. Carotid arterial stiffness in tobacco-free (n = 19)and snus-exposed children (n 
= 21). Result from Study 4. 
 
 
Our measurements of stiffness index are congruent with reports from 5‒10- year- old control 
children (131, 187). The stiffness index is calculated from pulsatile changes in blood pressure 
and diameter of the common carotid artery. The systolic carotid diameters were similar in 
snus-exposed and control children, but the diastolic carotid diameters were larger in snus- 
exposed children. Although this finding is not easily explained, one plausible explanation 
could be higher peripheral vascular resistance in the snus- exposed individuals. Consequently, 
a higher DBP would be expected. However, there was no significant difference in DBP, 
though the snus- exposed children had slightly higher values.    
The common carotid artery is a large elastic vessel with a thick developed tunica media with 
elastic fibers arranged in concentric layers. The compliance of the wall is dependent on the 
ratio between elastin and collagen proteins. Furthermore, factors like glycation proteins 
crosslinking with collagen and extracellular proteins are involved in complex processes that 
may reduce vessel compliance (188). Ageing processes, inflammation, hypertension and 
shear stress favor collagen production and undermine elastin synthesis (188). Prenatal 
exposure to nicotine disturbs the elastin production in pulmonary arteries of monkeys, 
resulting in stiffer vessels and increased pulmonary hypertension (189).   
 
In our study (Paper Ⅳ) there was no difference in cIMT between the snus- exposed and the 
tobacco-free controls. The connection between cigarette smoking and atherosclerosis is 
strong and thicker cIMT is an early sign of atherosclerotic disease (190, 191). The 
pathophysiological process of atherosclerosis is promoted by cigarette smoke through 
contribution of inflammation, insulin resistance, dyslipidemia, thrombosis and endothelial 
dysregulation.(192, 193) Nicotine is at least partly responsible for these changes and in 
addition, nicotine affects autonomic regulation with raised blood pressure as a consequence. 
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There are numerous studies in animals suggesting that arterial wall changes are associated 
with exposure to nicotine (194-197). Nevertheless, a study of adult snus users could not show 
any changes in cIMT (198). Pathological changes of the arterial wall characteristics, 
especially early in life, do not necessarily imply a beginning atherosclerotic process. Arterial 
stiffness due to prenatal nicotine exposure may be an entity of its own, disparate from ageing 
vessels in adult smokers.   
 
 
 
 
 
Figure 18. Arterial stiffness and cIMT (mm) in snus- exposed and control children. There 
is no correlation between arterial stiffness and cIMT. Results from Study 4. 
 
 
The scarce reports about maternal smoking and intima media wall changes in children are 
incongruent. In newborns, altered umbilical artery walls (199) and aortic walls (200) have 
been described, and in 5-year-old children exposed to cigarette smoke cIMT was increased 
(132). On the other hand, a report of 8-year-old children with both prenatal and second hand 
exposure during childhood did not show any changes in cIMT (201).  
 
5.6 INTERACTIONS BETWEEN THE AUTONOMIC NERVOUS SYSTEM AND 
BLOOD PRESSURE AND ARTERIAL WALL STIFFNESS 
The autonomic cardiac regulation in the 5‒6 year-old children was also altered, suggesting a 
long-term prenatal programming from nicotine exposure and not just a delayed maturation in 
the autonomic cardiac regulation (Paper ⅠⅠⅠ). The mechanism behind prenatal nicotine 
exposure and altered cardiac control and blood pressure regulation is not fully understood, 
but involves numerous reflexes and connecting systems.  
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The baroreceptor reflex loop and the renin-angiotensin-aldosterone system (RAAS) are 
involved in autonomic regulation of the blood pressure (202-204). We could see a correlation 
between LF/HF and the systolic blood pressures above the 60th centile in snus-exposed 
children, confirming a connection, although there was no correlation when including blood 
pressures and LF/HF from all snus-exposed children. An explanation could be that the 
strongest association with nicotine exposure and autonomic control is found in this higher 
range of SBP. Alternatively, the correlation could be explained by some outliers. The cutoff 
at the 60th centile was chosen as it exceeded the 95% CI of the controls and the median of the 
snus users was the 60th centile.  
Nicotine exerts a wide range of effects on the autonomic nervous system through binding to 
nAChR in the brain, autonomic ganglia, adrenal medulla and neuromuscular junction, and 
affects other neurotransmitter systems via both pre- and postsynaptic effects (96, 97). 
Furthermore, nicotine may also interfere with ANS and BP control via structural changes 
leading to physiological effects. Indeed, smaller kidneys have been described in children 
exposed to maternal smoking during pregnancy and a potential subsequent dysfunction in the 
RAAS (205, 206).  
The composition and characteristics of the arterial walls are of importance in blood pressure 
control, where a stiff and thick arterial wall increases resistance and may increase pressure. 
On the other hand, a high BP promotes shear stress on the arterial wall and the wall becomes 
thicker and stiffer in response to the increased pressure (207), see Figure 19.  
 
Figure 19. The response to increased pressure on the arterial wall with increased wall 
thickness and stiffness. Source: Adapted from Martyn et Greenwald, The Lancet 1997. 
Published with kind permission from Elsevier.  
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Arterial wall changes have been described in both neonates and older children following 
maternal smoking during pregnancy (199, 208). Prenatal nicotine exposure in monkeys also 
leads to thicker walls, increased collagen in adventitia and lowers the elastin compound in 
pulmonary arteries (189). Other animal studies show vascular dysfunction, endothelial 
dysfunction, increased response in SBP to angiotensin ⅠⅠ and impaired perivascular adipose 
tissue with effects on arterial contraction following prenatal nicotine exposure (194, 203, 209, 
210). The opposite connection between the arterial wall and ANS is not as clear and reports 
are rare, but endothelial function and NO seem to modulate the activity of sympathetic fibers 
in the arterial wall (211).  
Nicotinic involvement in the process of arterial wall changes is evident but the process is 
truly complex and the crosstalk between arterial wall function, blood pressure and autonomic 
control is intriguing (212, 213); they are linked, interconnected and they are all susceptible to 
nicotinic actions. 
 
Figure 20. The crosstalk between autonomic nervous system (ANS), blood pressure (BP) 
and arterial wall, under the influence of nicotine. 
 
5.7 BOYS MAY BE MORE VULNERABLE TO SNUS EXPOSURE 
It is well-known that boys are more likely to be affected by prenatal stressors: being born 
preterm, having poorer neonatal outcome and an having increased risk of SIDS (214). 
Although our cohorts were too small to allow stratified analysis of sex differences, we could 
see a trend where boys seemed more affected by nicotine exposure. In HRV analysis, the 
difference between controls and tobacco-exposed infants was larger in boys than in girls and 
a similar trend was seen in SBP in the 5‒6-year-old children. Arterial strain and stiffness did 
not show any tendencies towards sex differences at all. However, the cIMT measurements 
 44 
exposed a significant difference between boys and girls in the snus-exposed group which was 
more accentuated than in the control children.  
Although it is not possible to draw any conclusions from these tendencies, there are animal 
studies that support the theory of different responses in males following prenatal nicotine 
exposure. Such sex differences to prenatal nicotine exposure have been demonstrated in HRV 
(215), arterial contractility (209) and a stronger response in male rats BP after angiotensin ⅠⅠ 
stimulation (203). In humans, maternal smoking decreased RSA more in boys than in girls, 
which is interesting given that boys have higher risk of SIDS than girls. Studies of BP or 
cIMT in children following maternal smoking have not considered or reported any sex 
differences (132, 173, 175, 216). There are studies reporting sex differences in arterial wall 
composition in normal control children but the data are incongruent (133, 217).     
  
 
                          A                                                                B  
 
                                                          
 
                          C 
 
Altogether, these findings are merely indications of boys being more vulnerable to nicotine 
exposure and need to be further elaborated. It is important to recognize possibilities of sex 
differences when planning studies also in children, which requires a meticulous study design 
and the performance of subgroup analyses.    
Figure 21. Are boys more affected by 
nicotine? 
 A: Heart rate variability infants (Study 1) 
 B: Systolic blood pressure (Study 3) 
 C: Carotid intima media thickness (Study 4) 
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5.8 FUTURE ASPECTS 
This thesis has added important data increasing the understanding of prenatal tobacco 
exposure during vulnerable developmental periods and the associations with risk factors for 
future cardiovascular disease. However, it has also raised questions that need further studies.  
The main aim of this project was to study whether it is beneficial for the child if the mother 
uses snus instead of cigarettes and we believe that this thesis and other studies have answered 
that question. It is clearly not safe for the child to be exposed to snus during fetal life and 
there appear to be no safe periods or safe doses. It is therefore unclear what added data future 
studies of tobacco use during pregnancy could offer, beyond corroborating its harmful 
effects. Instead, future studies should focus on effective ways to help women quit tobacco 
and nicotine during pregnancy. This is not a new research field and many studies have 
addressed this issue, but effective measures remain to be defined, illustrating also the 
enormous addictive potential of nicotine use. Finding ways to help women quit their nicotine 
use during pregnancy has the potential to significantly improve child health and effects 
continuing into adulthood. It should thus be a highly prioritized research question. 
Although the harmful effects of nicotine exposure during gestation may be regarded as 
established, the present studies have indicated some specific areas that may be worthwhile to 
explore from a mechanistic point of view. 
Firstly, the effects and mechanisms involved in the adaptation of neuronal signaling systems 
to nicotine exposure remain unclear. This is illustrated by the complex response following 
nicotine depletion after a period of nicotine exposure during development. The underlying 
mechanisms behind this paradoxical response should be explored on a basic scientific level, 
including animal studies and cellular models.  
Secondly, the beneficial effects from breastfeeding need further exploration. The positive 
effects may be due to important constituents in breastmilk, i.e., anti-inflammatory and 
immune- stimulating factors ‒ or maybe breastfeeding reflects a mother in good health. 
Perhaps, being unable to breastfeed is a manifestation of the detrimental effects of tobacco on 
both the mother and the baby.       
Thirdly, the physiological role of the metabolite cotinine needs to be further investigated as 
this will be of great importance for the understanding of different physiological effects in an 
in vivo setting.  
Finally, the indications of important sex differences between girls and boys in several of the 
studies in this thesis need to be confirmed in studies sufficiently powered to perform analyses 
thereof. The underlying mechanism(s) for such differences is unclear, but our findings clearly 
point to the importance of future studies including testing of sex differences in children 
exposed to tobacco and nicotine.  
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5.9 CLINICAL CONSIDERATIONS AND PREVENTION  
Tobacco and nicotine products are not safe during pregnancy and should be avoided. 
Although there are indications of some associations between dose and negative outcome, 
there is no dose that is considered safe.  
We have showed that even early exposure matters and that there are no safe periods. Tobacco 
cessation program should be offered in Youth Health Guidance Centers and antenatal centers, 
before, during and after a pregnancy. Preferably, cessation should be achieved before 
conception (218), a recommendation supported by our findings of effects from early 
exposure. The support and abstention of the partner is important for successful tobacco 
cessation in the mother-to-be and the partner should be included in a cessation program. 
Advice and recommendations should be specific, scientific and easy to follow for both the 
tobacco user and the health care professionals. When it comes to recommendations for the 
group that really struggles with total abstention, the health care professionals find it 
challenging to advise on NRT and other nicotine products (219).  
According to the American Academy of Pediatrics Policy Statements “Clinical practice 
policy to protect children from tobacco, nicotine and tobacco smoke” from 2015 there is 
strong evidence for not recommending e-cigarettes as a cessation aid (220), it is actually 
associated with decreased rates of stopping smoking cigarettes in adolescence (220). 
The tobacco industry needs to be regulated through laws on advertising, labelling of products 
and introducing new tobacco or nicotine products. Restrictions of visibility and product 
layout in stores are effective actions. There is a need for regulations on new nicotine products 
and how they are presented and sold beside NRT products, as this may be confusing and 
misleading for a customer.   
More extensive laws regulating exposure to second hand smoke and limiting cigarette 
smoking in public areas are needed to make sure that children are protected from second hand 
smoke. The nicotine containing liquid used for e-cigarettes is highly toxic and many products 
candy or fruits flavors; there have been severe cases of poisoning in small children 
accidentally ingesting liquid nicotine (221, 222).   
Furthermore, preventive actions are needed to stop the next generation from developing a 
nicotine or tobacco addiction. One method could be to regulate smoking in movies and TV 
programs that may be seen by children. The American Academy of Pediatrics and the 2014 
General Surgeon’s report have addressed “movie smoking” as a problem and suggested that 
restricting smoking in movies could have a significant impact (220).  
Secondary prevention may also be considered. Babies to mothers who have used tobacco 
during pregnancy could be offered an examination and, if necessary, prescription of apnea 
alarms. A clinical examination of tobacco-exposed children in preschool age with blood 
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pressure check-up may be considered. Furthermore, if risk factors add up with prenatal 
nicotine exposure, increased systolic blood pressure, overweight, hereditary of hypertension 
and overweight, an intervention in early childhood might prevent future cardiovascular 
disease.    
 
5.10  CONCLUSION 
Maternal snus use during pregnancy showed long-lasting associations with altered autonomic 
cardiac control, increased systolic blood pressure and stiff arterial walls in the offspring, 
suggesting a prenatal programming from nicotine exposure. These alterations in 
cardiovascular function may follow a trajectory in to adult life with increased risk of future 
cardiovascular disease. Identifying early signs of cardiovascular risk factors during childhood 
may be of importance for preventive actions.  
Nicotine exposure even early in pregnancy matter and there are no safe periods during 
embryonic development and no safe level of nicotine exposure established. Women of 
childbearing age are therefore recommended to abstain from tobacco and nicotine in all forms 
during pregnancy and breastfeeding. 
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6 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Användningen av snus ökar i Sverige och Norge, även bland kvinnor i fertil ålder. Enligt 
Socialstyrelsen uppger 4,7% av kvinnor att de snusat tolv veckor före graviditeten. Under 
graviditeten uppger 1,3% av svenska kvinnor att de snusar.  
Snusare slipper de giftiga förbränningsprodukter som bildas i cigarettrök, dock innehåller 
snus höga doser av nikotin. Nikotinet passerar lätt över till fostret. Fostervattnet kan till och 
med innehålla högre nivåer av nikotin än vad man finner i mammans blod. Effekterna av 
exponering av nikotin under fosterlivet är inte helt klarlagda. Man har beskrivit ökad risk för 
fosterdöd, för tidig födsel, lägre födelsevikt, gomspalt och även ökad risk för död i 
nyföddhetsperioden. De liknar de risker som har beskrivits vid rökning under graviditet, även 
om barn till rökare har en mer uttalad risk för tillväxthämning. Den flerfaldigt ökade risken 
för plötslig spädbarnsdöd som föreligger vid rökning har inte kunnat visas hos barn till 
snusare.  
Vi ville undersöka om barn som exponerats för snus under fosterlivet uppvisade några 
effekter på hjärta och kärlsystem. Rökning under graviditet har rapporterats ge förändrad 
autonom reglering av hjärtrytmen, förhöjt blodtryck och stelare och förtjockade kärl. Denna 
hjärt- och kärlpåverkan tros bero på nikotin-exponernig under fosterlivet. Men tolkningen har 
försvårats av att cigarettrök innehåller tusentals andra potentiellt giftiga substanser. Dessutom 
har de flesta undersökningar gjorts på barn som även har varit utsatta för cigarettrök från 
föräldrarna under uppväxten. Genom att studera barn till snusare kunde vi utesluta 
exponering från andra giftiga substanser än nikotin och även utesluta effekter från fortsatt 
exponering under uppväxten.  
I vår första studie undersökte vi barn vid en till två månaders ålder vars mödrar snusat under 
en del av, alternativt hela, graviditeten. Barnens autonoma reglering av hjärtrytmen 
undersöktes med EKG och analys av hjärtfrekvensvariabilitet jämfördes I dessa hänseenden 
med barn till rökare och helt nikotin- och tobaksfria barn. Barn till både rökare och snusare 
uppvisade förändrad hjärtfrekvensvariabilitet jämfört med kontrollbarnen och denna 
förändring liknade den man tidigare har sett hos barn med ökad risk för plötslig 
spädbarnsdöd. Lite överraskande visade även de barn vars hade mödrar slutat med tobak 
tidigt under graviditeten en förändrad hjärtfrekvensvariabilitet. Vi drog slutsatsen att det inte 
finns någon säker period för tobak under fostertiden.  
Vi undersökte också nivåerna av nikotin och dess nedbrytningsprodukter i bröstmjölk hos 
snusande och rökande mammor. Nivåerna av nikotin var minst lika höga i bröstmjölk från 
snusare som I bröstmjölk från rökare. Dock var alla bröstmjölksprover från rökare fria från 
nikotin fyra timmar efter rökning, medan vi hos snusarna fortfarande kunde påvisa nikotin 
mer än 12 timmar efter senaste snusdos.  
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I studierna tre och fyra undersökte vi 5-6 åringar som hade varit exponerade för snus under 
hela fosterlivet och under amning. Dessa barn uppvisade högre systoliskt blodtryck jämfört 
med icke-exponerade barn och de hade också en förändrad hjärtfrekvensvariabilitet, trots att 
det hade gått så lång tid sen exponeringen upphört. Vi tolkar detta som att nikotin under 
fosterlivet hade gett upphov till långvariga effekter som kan ha betydelse för framtida hjärt- 
och kärlhälsa hos dessa individer.  
I studie fyra undersökte vi barnens halskärl och tittade på kärlets eftergivlighet och kärlets 
tjocklek, även kallat “intima media” tjocklek. Vi fann att barn till snusare hade stelare kärl 
jämfört med kontrollerna men ingen skillnad i kärltjocklek. Denna kärlstelhet kan vara ett 
förstadium till åderförkalkning och kan medföra en ökad risk för hjärtkärlsjukdomar senare 
under vuxenlivet.  
Sammanfattningsvis fann vi förändringar som kan innebära ökad risk för plötslig 
spädbarnsdöd och risk för utveckling av framtida hjärt- kärl sjukdomar. Vi tolkar det som att 
nikotinexponering under fosterlivet ger långvariga och potentiellt bestående förändringar som 
kan innebära en ökad risk för de exponerade individernas hälsa under vuxenlivet. Vår 
rekommendation är att avstå från alla former av tobak och nikotinprodukter under 
graviditeten. Även snusande kvinnor bör rekommenderas att amma sina barn, men om 
möjligt avstå från nikotin eller åtminstone minska doserna.     
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